HYFT MindWalk Holdings Corp.
Price Chart
Executive Summary
MindWalk reported preclinical dengue data showing that immunogens designed on a HYFT-computationally-predicted target elicited cross-reactive antibodies against all four dengue serotypes in two independent animal campaigns, with scrambled-sequence controls confirming specificity. This is the first public evidence of a closed prediction-to-result loop on the HYFT vaccine platform, supporting the platform's fundamental claim but remaining at the binding level only — neutralization and ADE data are pending.
Actionable Insight
The data provide initial platform validation for HYFT's AI-driven target discovery, which could support future partnership or licensing value. However, the result is binding-level only — neutralization and ADE data are the next critical catalysts. Monitor for functional study results and potential pharma partnership announcements.
Key Facts
- HYFT computationally identified a pan-serotype dengue target before immunization; subsequent immunization data support the binding-level prediction.
- Immunogens designed on the predicted target elicited antibodies that cross-react with antigens of all four dengue serotypes, reproduced across two independent campaigns with distinct immunogen formats and adjuvants.
- Scrambled-sequence controls did not show the same cross-serotype recognition, indicating response specificity.
- This is MindWalk's first public evidence of a closed prediction-to-result loop on its vaccine platform.
- Functional characterization (virus neutralization, ADE profile) has not been disclosed — the result is binding-level only.
- The same predictive capability is being deployed across MindWalk's influenza program and other multi-strain programs.
Financial Impact
No financial figures disclosed; the filing is a preclinical data readout with no revenue, earnings, or deal value.
Risk Factors
- Cross-reactive binding does not guarantee virus neutralization or avoidance of antibody-dependent enhancement (ADE).
- The program is at preclinical proof-of-concept stage — no clinical data, regulatory filings, or commercialization timeline.
- Forward-looking statements dominate the release; no hard financial or partnership milestones were announced.
- The company has an $81M market cap with no disclosed revenue from this platform — valuation is entirely speculative.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001715925-26-000003 |
| Document: hyft-ex99_1.htm | 0001715925-26-000003 |
| Document: 0001715925-26-000003-index-headers.html | 0001715925-26-000003 |
| Document: 0001715925-26-000003-index.html | 0001715925-26-000003 |
| Document: 0001715925-26-000003.txt | 0001715925-26-000003 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
6-K
| $1.69 awaiting T+1 | awaiting T+1 | — | $1.56 (−7.69%) |
|
Jun 10, 2026
2d ago
|
6-K
| $1.81 awaiting T+1 | awaiting T+1 | — | $1.56 (−13.81%) |
|
Jun 2, 2026
10d ago
|
6-K
| $1.97 $1.80 | ▼ −8.63% | ▼ −7.94% | $1.56 (−20.81%) |
|
May 27, 2026
16d ago
|
6-K
| $1.71 $1.79 | ▲ +4.68% | ▲ +4.13% | $1.56 (−8.77%) |
|
May 18, 2026
25d ago
|
6-K
| $1.26 $1.26 | · 0.00% | ▲ +0.65% | $1.56 (+23.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access